Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000491117 | SCV000580465 | pathogenic | Hereditary cancer-predisposing syndrome | 2020-11-12 | criteria provided, single submitter | clinical testing | The c.633delG pathogenic mutation, located in coding exon 3 of the MSH2 gene, results from a deletion of one nucleotide at nucleotide position 633, causing a translational frameshift with a predicted alternate stop codon (p.K212Nfs*2). This mutation (also designated as c.630delG) has been reported in Korean and Chinese hereditary non-polyposis colorectal cancer (HNPCC)/Lynch syndrome families (Yoon S et al. Cancer Genet. Cytogenet., 2009 Jan;188:61-4; Jiang W et al. Int J Cancer, 2019 05;144:2161-2168). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Myriad Genetics, |
RCV003449348 | SCV004186849 | pathogenic | Lynch syndrome 1 | 2023-07-27 | criteria provided, single submitter | clinical testing | This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. |